Beam Therapeutics Inc.
BEAMNASDAQHealthcareBiotechnology
As of Oct 15, 2026 close
- Market cap
- $2.58B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $20.23$38.26
- Volume (live)
- -
- Avg. volume (3M)
- 1.97M
Beam Therapeutics (BEAM) Stock Price & Financial Analysis
Beam Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $23.20 - $24.98 |
|---|---|
| 52-Week High | $38.26 |
| 52-Week Low | $20.23 |
| Open | $23.51 |
| Volume (last close) | 1.78M |
| Average Volume (3M) | 1.97M |
| Revenue (TTM) | 156.03M |
|---|---|
| Net Income (TTM) | -85.43M |
| Free Cash Flow (TTM) | -372.77M |
| EPS (TTM) | −$0.82 |
| Profit Margin | -54.75% |
| Operating Margin | -242.27% |
| Return on Equity (ROE) | -8.00% |
| Debt to Equity | 0.11 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 2.58B |
|---|---|
| Shares Outstanding | 104.33M |
| Price to Sales (P/S) | 16.53 |
| Price to Book (P/B) | 2.42 |
| EV/EBITDA | -29.68 |
| 50-Day MA | $26.38 |
|---|---|
| 200-Day MA | $28.39 |
| 1-Year Change | −4.11% |
Source: Market prices and company fundamentals. Data as of Oct 15, 2026. Data sources and methodology
Beam Therapeutics at a Glance
As of the Oct 15, 2026 close, Beam Therapeutics (BEAM) has a market capitalization of $2.58B. The stock trades at 16.5× sales. Over the trailing twelve months it lost $85.43M on revenue of $156.03M and burned $372.77M of free cash flow. Revenue grew 158.9% year over year.
As of its latest reported balance sheet, it holds $219.82M in cash and securities against $115.47M of debt, a net cash position of $104.36M.
Beam Therapeutics does not currently pay a dividend.
The share price is down 4.1% over the past year. At $24.73 (the Oct 15, 2026 close) it sits within its 52-week range of $20.23 to $38.26, below its 200-day moving average of $28.39.
Based on 14 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $53.91, 118.0% above the Oct 15, 2026 close.
Frequently Asked Questions About Beam Therapeutics
What is the current stock price for BEAM?
As of the Oct 15, 2026 close, BEAM stock trades at $24.73. The 52-week range is $20.23–$38.26, with a day range of $23.20–$24.98.
What is the P/E ratio for BEAM?
The P/E ratio (Price-to-Earnings) for BEAM is shown in the Key Statistics section. This valuation metric helps compare Beam Therapeutics Inc. to industry peers.
Does BEAM pay dividends?
Beam Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BEAM?
Based on ratings from 14 professional analysts over the last 90 days, the consensus for BEAM is Buy. The average 12-month price target is $53.91, a 118.0% upside from the Oct 15, 2026 close of $24.73.
What is the market cap of BEAM?
As of the Oct 15, 2026 close, Beam Therapeutics's market capitalization is $2.58B, classifying it as a mid-cap company. Beam Therapeutics operates in the Healthcare sector within the Biotechnology industry.